Inovio Pharmaceuticals, INOhas initiated a phase II study to evaluate the efficacy of its pipeline candidate VGX-3100 on adult men and women with human papilloma virus (HPV)-related anal dysplasia. This will be the third indication that VGX-3100 will be evaluated for. It is already being evaluated to treat HPV-related vulvar and anal precancers.
Inovio Initiates Phase II Study on Pipeline Drug VGX-3100
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться